Takashi Eguchi, MD, PhD

Research Fellow

Takashi Eguchi, MD, PhD

Research Fellow

Start Year


End Year



  • Shinshu University Research Scholarship Research Scholarship

Current Employment

  • Senior Assistant Professor, Division of General Thoracic Surgery, Department of Surgery, Shinshu University School of Medicine, Japan


  • Zeltsman M, Dozier J, Vaghjiani RG, Poch A, Eguchi T, Pedoto A, Jones DR, Adusumilli PS. Decreasing use of epidural analgesia with increasing minimally invasive lobectomy: impact on postoperative morbidity. Lung Cancer. 2019;139, 68-72.
  • Hristov B, Eguchi T, Bains S, Dycoco J, Tan KS, Isbell JM, Park BJ, Jones DR, Adusumilli PS. Minimally invasive lobectomy is associated with lower noncancer-specific mortality in elderly patients: a propensity score matched competing risks analysis. Ann Surg. 2019;270(6):1161-1169.
  • Emoto K, Eguchi T, Tan KS, Takahashi Y, Aly RG, Rekhtman N, Travis WD, Adusumilli PS, Travis WD. Expansion of the concept of micropapillary adenocarcinoma to include a newly recognized filigree pattern as well as the classical pattern based on 1468 stage I lung adenocarcinomas. J Thorac Oncol. 2019;14(11):1948-1961.
  • Li X, Eguchi T, Aly RG, Chintala NK, Tan KS, Zauderer MG, Dembitzer FR, Beasley MB, Ghebrehiwet B, Adusumilli PS, Peerschke EB. Globular C1q receptor (gC1qR/p32/HABP1) is overexpressed in malignant pleural mesothelioma and is associated with increased survival in surgical patients treated with chemotherapy. Front Immunol. 2019;9:1042.
  • Muller S, Victoria Lai W, Adusumilli PS, Desmeules P, Frosina D, Jungbluth A, Ni A, Eguchi T, Travis WD, Ladanyi M, Zauderer MG, Sauter JL. V-domain Ig-containing suppressor of T-cell activation (VISTA), a potentially targetable immune checkpoint molecule, is highly expressed in epithelioid malignant pleural mesothelioma. Mod Pathol. 2019; [Epub ahead of print]
  • Tan KS, Eguchi T, Adusumilli PS. Reporting net survival in populations: a sensitivity analysis in lung cancer demonstrates the differential implications of reporting relative survival and cause-specific survival. Clin Epidemiol. 2019;11:781-792.
  • Aly RG, Rekhtman N, Li, Takahashi Y, Eguchi T, Tan KS, Rudin C, Adusumilli PS, Travis WD. Spread through air spaces (STAS) is prognostic in atypical carcinoid, large cell neuroendocrine carcinoma, and small cell carcinoma of the lung. J Thorac Oncol. 2019;14(9):1583-1593.
  • Qu Y, Emoto K, Eguchi T, Aly RG, Zheng H, Chaft JE, Tan KS, Jones DR, Kris MG, Adusumilli PS, Travis WD. Pathologic assessment after neoadjuvant chemotherapy for non-small cell lung cancer: Importance and implications of distinguishing adenocarcinoma from squamous cell carcinoma. J Thorac Oncol. 2019 Mar;14(3):482-493.
  • Bains S, Eguchi T, Warth A, Yeh YC, Nitadori JI, Woo KM, Chou TY, Dienemann H, Muley T, Nakajima J, Shinozaki-Ushiku A, Wu YC, Lu S, Kadota K, Jones DR, Travis WD, Tan KS, Adusumilli PS. Procedure-specific risk prediction for recurrence in patients undergoing lobectomy or sublobar resection for small (</=2 cm) lung adenocarcinoma: an international cohort analysis. J Thorac Oncol. 2019;14(1):72-86.
  • Eguchi T, Kameda K, Lu SH, Bott MJ, Tan KS, Montecalvo J, Chang JC, Rekhtman N, Jones DR, Travis WD, Adusumilli PS. Lobectomy is associated with better outcomes than sublobar resection in spread through air spaces (STAS)-positive T1 lung Adenocarcinoma: a propensity score-matched analysis. J Thorac Oncol. 2019;14(1):87-98.
  • Kameda K, Eguchi T, Lu S, Qu Y, TanKS, Kadota K, Adusumilli PS, Travis WD. Implications of the eighth edition of the TNM proposal: invasive vs. total tumor size for the T descriptor in pathologic stage I-IIA lung adenocarcinoma. J Thorac Oncol. 2018;13(12):1919-1929.
  • Takahashi Y, Eguchi T, Kameda K, Lu S, Vaghjiani RG, Tan KS, Travis WD, Jones DR, Adusumilli PS. Histologic subtyping in pathologic stage I-IIA lung adenocarcinoma provides risk-based stratification for surveillance. Oncotarget. 2018;9(87):35742-35751.
  • Takahashi Y, Eguchi T, Lu S, Downey RJ, Jones DR, Travis WD, Adusumilli PS. Preponderance of high-grade histologic subtype in autologous metastases in lung adenocarcinoma. Am J Respir Crit Care Med. 2018;155(3):1203-1204.
  • Bucciarelli PR, Tan KS, Chudgar NP, Brandt W, Montecalvo J, Eguchi T, Liu Y, Aly R, Travis WD, Adusumilli PS, Jones DR. BRMS1 expression in surgically resected lung adenocarcinoma predicts future metastases and is associated with a poor prognosis. J Thorac Oncol. 2018;13(1):73-84.
  • Tan KS, Eguchi T, Adusumilli PS. Competing risks and cancer-specific mortality: why it matters. Oncotarget. 2018;9(7):7272-3.
  • Eguchi T, Kadota K, Mayor M, Zauderer MG, Rimner A, Rusch VW, Travis WD, Sadelain M, Adusumilli PS. Cancer antigen profiling for malignant pleural mesothelioma immunotherapy: expression and coexpression of mesothelin, cancer antigen 125, and Wilms tumor 1. Oncotarget. 2017;8(44):77872-82.
  • Zheng H, Zeltsman M, Zauderer MG, Eguchi T, Vaghjiani RG, Adusumilli PS. Chemotherapy-induced immunomodulation in non-small-cell lung cancer: a rationale for combination chemoimmunotherapy. Immunotherapy. 2017;9(11):913-27.
  • Eguchi T, Adusumilli PS. Risk stratification for lung nodules: size isn’t everything. J Thorac Cardiovasc Surg. 2017;153(6):1557-62.
  • Eguchi T, Adusumilli PS. Competing risks analysis in the prognostic assessment of patients undergoing lung resection. J Thorac Dis. 2017;9(4):E395-E7.
  • Lu S, Tan KS, Kadota K, Eguchi T, Bains S, Rekhtman N, Adusumilli PS, Travis WD. Spread through air spaces (STAS) is an independent predictor of recurrence and lung cancer specific death in squamous cell carcinoma. J Thorac Oncol. 2017;12(2):223-234.
  • Eguchi T, Bains S, Lee MC, Tan KS, Hristov B, Buitrago DH, Bains MS, Downey RJ, Huang J, Isbell JM, Park BJ, Rusch VW, Jones DR, Adusumilli PS. Impact of increasing age on cause-specific mortality and morbidity in patients with stage I non-small c ell lung cancer: a competing risks analysis. J Clin Oncol. 2017;35(3):281-90.
  • Eguchi T, Kadota K, Chaft J, Evans B, Kidd J, See Tan K, Dycoco J, Kolquist K, Davis T, Hamilton SA, Yager K, Jones JT, Travis WD, Jones DR, Hartman AR, Adusumilli PS. Cell cycle progression score is a marker for five-year lung cancer-specific mortality risk in patients with resected stage I lung adenocarcinoma. Oncotarget. 2016;7(23):35241-56.
  • Takahashi Y, Eguchi T, Bains S, Adusumilli PS. Significance of IASLC/ATS/ERS classification for early-stage lung adenocarcinoma patients in predicting benefit from adjuvant chemotherapy. Ann Transl Med. 2016;4(4):66.
  • Kadota K, Eguchi T, Villena-Vargas J, Woo KM, Sima CS, Jones DR, Travis WD, Adusumilli PS. Nuclear estrogen receptor-alpha expression is an independent predictor of recurrence in male patients with pT1aN0 lung adenocarcinomas, and correlates with regulatory T-cell infiltration. Oncotarget. 2015;6(29):27505-18.
  • Eguchi T, Kadota K, Park BJ, Travis WD, Jones DR, Adusumilli PS. The new IASLC-ATS-ERS lung adenocarcinoma classification: what the surgeon should know. Semin Thorac Cardiovasc Surg. 2014;26(3):210-22.